PIK3CA act mut
Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene PIK3CA
Variant act mut
Impact List unknown
Protein Effect gain of function
Gene Variant Descriptions PIK3CA act mut indicates that this variant results in a gain of function in the Pik3ca protein. However, the specific amino acid change has not been identified.
Associated Drug Resistance
Category Variants Paths

PIK3CA mutant PIK3CA act mut

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02549989 Phase II LY3023414 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Completed USA 0
NCT04108858 Phase Ib/II Copanlisib + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Terminated USA 0
NCT05392608 Phase II Alpelisib + Fulvestrant SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) (SEQUEL-Breast) Active, not recruiting NLD 0
NCT05300048 Phase I Serabelisib Nab-paclitaxel + Serabelisib Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Completed USA 0
NCT01833169 Phase II Buparlisib BKM120 for Patients With PI3K-activated Tumors Completed USA 0
NCT05039801 Phase I Capivasertib + IACS-6274 Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Recruiting USA 0
NCT03673787 Phase Ib/II Atezolizumab + Ipatasertib A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP) Active, not recruiting GBR 0
NCT05090358 Phase II Alpelisib + Fulvestrant Alpelisib + Canagliflozin + Fulvestrant Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer Active, not recruiting USA 0
NCT05759949 Phase I Fulvestrant + RLY-5836 RLY-5836 Fulvestrant + Palbociclib + RLY-5836 Abemaciclib + Fulvestrant + RLY-5836 Fulvestrant + Ribociclib + RLY-5836 First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors Completed USA 0
NCT05111561 Phase I Binimetinib + ZEN-3694 Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer Suspended USA 0
NCT04486352 Phase Ib/II Atezolizumab + Talazoparib Atezolizumab + Ipatasertib Abemaciclib + Giredestrant Inavolisib + Letrozole A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP) Recruiting USA 0
NCT05332561 Phase II Olaparib Ipatasertib Sacituzumab govitecan-hziy Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) Recruiting DEU 0
NCT06993844 Phase Ib/II ETX-636 ETX-636 + Fulvestrant Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT05154487 Phase II Alpelisib + Fulvestrant A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer Recruiting USA 0
NCT02920450 Phase Ib/II Carboplatin + Gedatolisib + Paclitaxel Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) Terminated USA 0
NCT05010096 Phase I Copanlisib + Elimusertib BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors Withdrawn 0
NCT02761694 Phase I ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations Terminated USA 0
NCT05216432 Phase I Fulvestrant + Ribociclib + RLY-2608 RLY-2608 Fulvestrant + RLY-2608 Fulvestrant + Palbociclib + RLY-2608 Fulvestrant + PF-07220060 + RLY-2608 First-in-Human Study of Mutant-selective PI3Kalpha Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer Recruiting USA | ITA | FRA | ESP | AUS 0
NCT03213678 Phase II LY3023414 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Completed USA 1
NCT04551521 Phase II Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib CRAFT: The NCT-PMO-1602 Phase II Trial Completed DEU 0
NCT04632992 Phase II Ipatasertib Atezolizumab + Capecitabine Entrectinib Atezolizumab + Docetaxel Ado-trastuzumab emtansine + Atezolizumab Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Alectinib Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab + Paclitaxel Ado-trastuzumab emtansine + Tucatinib A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC) Completed USA 0
NCT05230810 Phase Ib/II Alpelisib + Fulvestrant + Tucatinib Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. Recruiting USA 0
NCT05307705 Phase I Abemaciclib + Anastrozole + LOXO-783 Abemaciclib + Exemestane + LOXO-783 Abemaciclib + Letrozole + LOXO-783 LOXO-783 + Paclitaxel Fulvestrant + LOXO-783 Imlunestrant + LOXO-783 Abemaciclib + Fulvestrant + LOXO-783 Abemaciclib + Imlunestrant + LOXO-783 Letrozole + LOXO-783 LOXO-783 Anastrozole + LOXO-783 Exemestane + LOXO-783 A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01) Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT07174336 Phase III Letrozole + Palbociclib Fulvestrant + Palbociclib + STX-478 Anastrozole + Palbociclib Fulvestrant + Ribociclib + STX-478 Abemaciclib + Anastrozole + STX-478 Letrozole + Palbociclib + STX-478 Abemaciclib + Exemestane + STX-478 Letrozole + Ribociclib + STX-478 Abemaciclib + Fulvestrant + STX-478 Fulvestrant + Palbociclib Exemestane + Palbociclib Anastrozole + Palbociclib + STX-478 Abemaciclib + Letrozole + STX-478 Anastrozole + Ribociclib + STX-478 Exemestane + Palbociclib + STX-478 Exemestane + Ribociclib + STX-478 A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Recruiting USA | TUR | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG 3
NCT05843253 Phase II Ribociclib + Temozolomide Everolimus + Ribociclib Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Recruiting USA | NLD | GBR | DEU | CAN | AUS 0
NCT04317105 Phase Ib/II Copanlisib + Ipilimumab + Nivolumab Copanlisib + Nivolumab Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Active, not recruiting USA | CAN 0
NCT06736704 Phase I Fulvestrant + SNV4818 SNV4818 SNV4818 in Participants with Advanced Solid Tumors Recruiting USA | CAN | AUS 0
NCT05082025 Phase II Copanlisib + Fulvestrant Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Active, not recruiting USA 0
NCT03941782 Phase 0 Alpelisib Compassionate Use of BYL 719 Alpelisib No longer available USA 0
NCT03317119 Phase I Trametinib + Trifluridine-tipiracil hydrochloride Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery Completed USA 0
NCT04216472 Phase II Alpelisib + Nab-paclitaxel Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations Terminated USA 0
NCT06764186 Phase III Capivasertib + Fulvestrant A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain (CAPItana) Recruiting ESP 0
NCT06982521 Phase III Fulvestrant + RLY-2608 Capivasertib + Fulvestrant Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer (ReDiscover-2) Recruiting USA 0
NCT05300048 Phase I Serabelisib Nab-paclitaxel + Serabelisib Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Completed USA 0